scholarly journals COMPARISON AND EVALUATION OF TACROLIMUS VS STEROID THERAPY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN ACTIVE PHASE

2021 ◽  
Vol 9 (02) ◽  
pp. 644-654
Author(s):  
Zeba Samreen ◽  
◽  
Minhaj Sultana ◽  
Mohd Shanawazuddin ◽  
Tahoora Zainab ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Remission Rate ◽  
Active Phase ◽  
Initial Therapy ◽  
Efficacy And Safety ◽  
Short Term ◽  
Inflammatory Bowel

Background:-The aim of the study is to compare and evaluate the efficacy and safety of short-term outcomes of tacrolimus in inflammatory bowel disease (IBD) patients who were not concomitantly receiving other immunosuppressive therapies by carrying out an observational prospective study of tacrolimus (TAC) v/s corticosteroid (CS) therapy in the treatment of IBD in active phase, to prevent patient from long term use of CS by reducing the incidence rate of flare. To use TAC as a step-up approach in IBD by early induction of remission and maintain it for longer period which reduces re-hospitalization and surgery rate hence improving quality of life. Method And Material:-The study was conducted in gastroenterology department, Princess Esra hospital, Hyd. 50 patients were enrolled based on our inclusion and exclusion criteria, allocated in 2 groups receiving CS and TAC respectively for 10 days. Follow-ups were done and at the end of 2 months, again a colonoscopy was performed to assess the effectiveness of the treatment. Results:-At an initial therapy of 2 months, clinical remissions were observed in most of the patients of both the groups. After six months of treatment, TAC showed 100% remission rate while 20% patients on CS have shown flare. Conclusion:- prolongs period of remission, and prevents the long-term use of CS thereby preventing its complications proving step-up to be a better approach towards the management of IBD. This study concludes that the efficacy and safety profile of TAC was overall favorable, and the doses were well tolerated by most of the patients.

Short‐term and long‐term outcomes of indigo naturalis treatment for inflammatory bowel disease

2019 ◽  
Vol 35 (3) ◽  
pp. 412-417 ◽  
Author(s):  
Yuichi Matsuno ◽  
Atsushi Hirano ◽  
Takehiro Torisu ◽  
Yasuharu Okamoto ◽  
Yuta Fuyuno ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Long Term Outcomes ◽  
Short Term ◽  
Indigo Naturalis ◽  
Inflammatory Bowel

Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease

2020 ◽  
Vol 51 (9) ◽  
pp. 870-879 ◽  
Author(s):  
Iago Rodríguez-Lago ◽  
Jesús Castro-Poceiro ◽  
Agnès Fernández-Clotet ◽  
Francisco Mesonero ◽  
Antonio López-Sanromán ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Response ◽  
Bowel Disease ◽  
Short Term ◽  
Inflammatory Bowel

scholarly journals P292 Effect of drug therapy on the lipid profiles of patient with Inflammatory Bowel Disease: a systematic review and meta-analysis

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S322-S323
Author(s):  
J A M Sleutjes ◽  
J E Roeters van Lennep ◽  
E Boersma ◽  
A C de Vries ◽  
C J van der Woude
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Random Effect ◽  
Random Effect Model ◽  
Lipid Levels ◽  
Short Term ◽  
Cvd Risk ◽  
Drug Classes ◽  
Inflammatory Bowel

Abstract Background Increases of lipid levels associated with inflammatory bowel disease (IBD) medication have been previously reported. However, it is unknown whether this effect is similar for all IBD drug classes. Methods We performed a systematic literature search of randomized controlled trials and observational cohort studies of IBD treatment with corticosteroids, anti TNFα agents and tofacitinib that assessed total cholesterol (TC) before and after short-term (≤8 week) and long-term (≥12 week) treatment. Data of 11 studies (1,663 IBD patients) were pooled using a random effect model with as primary outcome TC levels. Lipid changes were reported as mean difference on the log2-scale (MDlog2) with 95% CI. The effect of patient and disease characteristics on TC changes were analyzed in 6 studies with individual patient data of 1,211 patients. Results A significant increase in TC was observed after treatment with corticosteroids, anti TNFα agents and tofacitinib (short-term +0.370, +0.197 and +0.190; long-term: +0.452, +0.068 and +0.162, respectively). (Figure 1) After correcting for age, sex, BMI and CRP, increases of TC levels after start of corticosteroids and tofacitinib treatment were higher (short-term: +0.293 and +0.161; long-term: +0.090 and +0.127, respectively) as compared to anti TNFα agents (short-term: -0.059, long-term: +0.041). (Figure 2) Conclusion Changes in lipid levels differ between IBD drug classes. TC levels increase was strongest for corticosteroids followed by tofacitinib but not observed for anti TNFα agents. Whether TC change associated with IBD treatment has effect on CVD risk requires further study.

scholarly journals Lower Level of Bacteroides in the Gut Microbiota Is Associated with Inflammatory Bowel Disease: A Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Yingting Zhou ◽  
Fachao Zhi
Keyword(s):  
Inflammatory Bowel Disease ◽  
Gut Microbiota ◽  
Bowel Disease ◽  
Meta Analysis ◽  
Active Phase ◽  
Cochrane Library ◽  
Control Group ◽  
Inflammatory Bowel ◽  
Normal Controls

Background and Aims. Multiple studies have reported associations between inflammatory bowel disease (IBD) and the flora disequilibrium of Bacteroides. We performed a meta-analysis of the available data to provide a more precise estimate of the association between Bacteroides level in the gut and IBD. Methods. We searched PubMed/MEDLINE, EMBASE, Cochrane Library, Wiley Library, BIOSIS previews, Web of Science, CNKI, and ScienceDirect databases for published literature on IBD and gut microbiota from 1990 to 2016. Quality of all eligible studies was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS). We compared the level of Bacteroides in IBD patients with that in a control group without IBD, different types of IBD patients, and IBD patients with active phase and in remission. Results. We identified 63 articles, 9 of which contained sufficient data for evaluation. The mean level of Bacteroides was significantly lower in Crohn’s disease (CD) and ulcerative colitis (UC) patients in active phase than in normal controls. The level of Bacteroides in remission CD and UC patients was much lower than patients in the control group. Bacteroides level was even lower in patients with CD and UC in active phase than in remission. Conclusions. This analysis suggests that lower levels of Bacteroides are associated with IBD, especially in active phase.

Sign in / Sign up

Export Citation Format

Share Document